[go: up one dir, main page]

MX2013001272A - Nuevo tratamiento del carcinoma de prostata. - Google Patents

Nuevo tratamiento del carcinoma de prostata.

Info

Publication number
MX2013001272A
MX2013001272A MX2013001272A MX2013001272A MX2013001272A MX 2013001272 A MX2013001272 A MX 2013001272A MX 2013001272 A MX2013001272 A MX 2013001272A MX 2013001272 A MX2013001272 A MX 2013001272A MX 2013001272 A MX2013001272 A MX 2013001272A
Authority
MX
Mexico
Prior art keywords
plumbagin
treatment
combination therapy
prostate carcinoma
naphthoquinone
Prior art date
Application number
MX2013001272A
Other languages
English (en)
Other versions
MX345788B (es
Inventor
Per Borgstroem
Original Assignee
Pellficure Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pellficure Pharmaceuticals Inc filed Critical Pellficure Pharmaceuticals Inc
Publication of MX2013001272A publication Critical patent/MX2013001272A/es
Publication of MX345788B publication Critical patent/MX345788B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

En este documento se dan a conocer análogos de naftoquinona, tales como plumbagina, una composición farmacéutica que incluye análogos de naftoquinona tales como plumbagina, y métodos de tratamiento de enfermedades y/o afecciones tales como cáncer con análogos de naftoquinona, tales como plumbagina. Además son incluidas combinaciones de terapias en donde un análogo de naftoquinona, tal como plumbagina, y un agente de terapia hormonal son proporcionados a un sujeto que padece de una afección tal como el cáncer.
MX2013001272A 2010-08-04 2011-08-03 Nuevo tratamiento del carcinoma de prostata. MX345788B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37053410P 2010-08-04 2010-08-04
PCT/US2011/046474 WO2012018948A2 (en) 2010-08-04 2011-08-03 Novel treatment of prostate carcinoma

Publications (2)

Publication Number Publication Date
MX2013001272A true MX2013001272A (es) 2013-05-22
MX345788B MX345788B (es) 2017-02-15

Family

ID=44504259

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001272A MX345788B (es) 2010-08-04 2011-08-03 Nuevo tratamiento del carcinoma de prostata.

Country Status (11)

Country Link
US (5) US9132105B2 (es)
EP (1) EP2600855A2 (es)
JP (1) JP5998137B2 (es)
KR (3) KR101823275B1 (es)
CN (1) CN103124563B (es)
AU (1) AU2011285724B2 (es)
BR (1) BR112013002655A2 (es)
CA (1) CA2807149C (es)
IL (1) IL224370B (es)
MX (1) MX345788B (es)
WO (1) WO2012018948A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2600855A2 (en) 2010-08-04 2013-06-12 Pellficure Pharmaceuticals, Inc. Combination therapy for the treatment of prostate carcinoma
CN102617664A (zh) * 2012-04-14 2012-08-01 广西师范大学 白花丹素-5-o-葡萄糖及其合成方法和应用
EP2844237A4 (en) * 2012-04-30 2015-11-25 Univ King Abdullah Sci & Tech GUIDANCE AGAINST CANCER
KR101388776B1 (ko) 2012-07-31 2014-04-23 성균관대학교산학협력단 2，3―비스［（2―하이드록시에틸）티오］―1，4―나프토퀴논을 포함하는 항염증용 조성물
AU2013323861C1 (en) 2012-09-26 2024-05-02 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
WO2014060358A1 (en) * 2012-10-15 2014-04-24 Chamaeleo Pharma Bvba Fosfestrol for use in curative or palliative treatment of cancer in female mammals
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
WO2014158875A1 (en) * 2013-03-14 2014-10-02 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
CA2905649A1 (en) * 2013-03-15 2014-09-18 The Penn State Research Foundation Compositions and methods including celecoxib and plumbagin relating to treatment of cancer
WO2016040896A1 (en) * 2014-09-12 2016-03-17 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
WO2016135633A1 (en) * 2015-02-24 2016-09-01 King Abdullah University Of Science & Technology Cholesteryl ester transfer protein (cetp) inhibition in the treatment of cancer
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
US11459295B2 (en) 2015-10-22 2022-10-04 The Trustees Of The University Of Pennsylvania 2-beta-naphthyl-acetic acid analogs as AKR1C3 inhibitors and methods of using same
AU2017350690A1 (en) * 2016-10-24 2019-06-13 Pellficure Pharmaceuticals Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
PE20191745A1 (es) 2016-12-06 2019-12-12 Ic Medtech Corp Compuestos de acido ascorbico y quinona para el tratamiento de la enfermedad de chagas
WO2018195202A1 (en) * 2017-04-21 2018-10-25 Pellficure Pharmaceuticals Inc. Compositions and methods for the treatment of cancer
KR101990054B1 (ko) * 2017-04-25 2019-06-17 대구대학교 산학협력단 로손을 유효성분으로 포함하는 항암 조성물
CN111479560A (zh) 2017-10-16 2020-07-31 阿拉贡药品公司 用于治疗非转移性去势难治性前列腺癌的抗雄激素
CN107879958B (zh) * 2017-10-30 2019-07-19 黑龙江八一农垦大学 2-(4-甲氧基苯巯基)-5,8-二甲氧基-1,4-萘醌及其制备方法和含其的药物
CN108645927A (zh) * 2018-05-03 2018-10-12 四川农业大学 一种利用hplc测定蓝花丹中白花丹素含量的方法
AR115493A1 (es) 2018-06-06 2021-01-27 Ic Medtech Corp Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias
JP2022524756A (ja) * 2019-03-06 2022-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 置換された二環式および四環式キノン類および関連する使用方法
CN113133984A (zh) * 2020-01-20 2021-07-20 鲁南制药集团股份有限公司 一种cyp17抑制剂的制剂
CN113134007B (zh) * 2020-01-20 2024-01-30 鲁南制药集团股份有限公司 一种醋酸阿比特龙口服制剂及其制备方法
US20250312409A1 (en) * 2022-05-10 2025-10-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of treating dilated cardiomyopathy and heart failure
CN118831075B (zh) * 2024-09-12 2026-01-27 中国医科大学 一种延缓骨骼肌衰老的复方药物及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3431236A1 (de) 1984-08-24 1986-02-27 Carnivora-Deutschland GmbH, 7109 Jagsthausen Verwendung von 1,4-naphthochinon-derivaten in niedrigen konzentrationen zur immunstimulation
CA1326234C (en) 1987-04-22 1994-01-18 Michael R. Angelastro 17.beta.-(cyclopropylamino)androst-5-en-3.beta.-ol and related compoundsuseful as_c__-__ lyase inhibitors
US4966898A (en) 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
WO1992000748A1 (en) 1990-07-06 1992-01-23 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5457102A (en) 1994-07-07 1995-10-10 Janssen Pharmaceutica, N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives
WO1993020097A1 (en) 1992-03-31 1993-10-14 British Technology Group Ltd. 17-substituted steroids useful in cancer treatment
CN1095275A (zh) * 1993-05-13 1994-11-23 江远辉 一种治疗前列腺增生的注射液
GB9310635D0 (en) 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
NZ273681A (en) 1993-09-30 1996-09-25 Yamanouchi Pharma Co Ltd Fluoroenylmethylazole derivatives (including tricyclic ring systems where the middle ring is heterosubstituted)
US5677293A (en) 1993-10-27 1997-10-14 Merrell Pharmaceuticals Inc. 16 unsaturated C17 heterocyclic steroids useful as steroid C17-20 lyase inhibitors
WO1996014090A1 (en) 1994-11-07 1996-05-17 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
AU6015796A (en) 1995-06-14 1997-01-15 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
US5994334A (en) 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
EP1028110B1 (en) 1997-10-02 2004-04-14 Daiichi Pharmaceutical Co., Ltd. Novel dihydronaphthalene compounds and process for producing the same
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
CA2328973A1 (en) 1998-04-23 1999-10-28 Akio Ojida Naphthalene derivatives, their production and use
WO2003027085A2 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
JP4502641B2 (ja) 2002-01-24 2010-07-14 ティルタン ファーマ リミテッド 抗癌組み合わせおよびその使用方法
WO2004060402A1 (de) 2002-12-28 2004-07-22 Gradl-Grams, Marianne Verfahren sowohl als stoff zur spezifischen proliferationsförderung von lymphozytensubpopulationen durch eine kombination eines immunmodulators mit einem nichtwasserlöslichen naturstoff und einem carrier
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
GB0324483D0 (en) 2003-10-21 2003-11-19 Psi Medica Ltd Composite material
WO2005053609A2 (en) * 2003-11-26 2005-06-16 Guilford Pharmaceuticals Inc. Methods of nad+-dependent deacetylase inhibitors
CN101037447B (zh) 2006-03-17 2010-09-08 广西师范大学 以白花丹素为配体的金属配合物、其合成方法及其用途
EP2034835B1 (en) * 2006-06-16 2019-05-15 Summa Health System Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
WO2008064311A2 (en) 2006-11-21 2008-05-29 Viamet Pharmaceuticals, Inc. Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties
AU2009223653B2 (en) 2008-03-10 2014-07-31 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
GB2479337A (en) 2009-02-05 2011-10-05 Tokai Pharmaceuticals Inc Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
NZ596488A (en) 2009-06-26 2012-11-30 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
CA2785898C (en) 2009-12-31 2018-07-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2011130692A2 (en) 2010-04-16 2011-10-20 Colby Pharmaceutical Company Androgen induced oxidative stress inhibitors
KR101379370B1 (ko) 2010-04-24 2014-03-28 비아멧 파마슈티컬즈, 인코포레이티드 금속효소 억제제 화합물
EP2600855A2 (en) * 2010-08-04 2013-06-12 Pellficure Pharmaceuticals, Inc. Combination therapy for the treatment of prostate carcinoma
US9056855B2 (en) 2010-10-28 2015-06-16 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EA024197B1 (ru) 2010-11-13 2016-08-31 Иннокрин Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
WO2012158884A1 (en) 2011-05-17 2012-11-22 Takeda Pharmaceutical Company Limited Pharmaceutical compositions and methods for treating cancer
WO2014158875A1 (en) 2013-03-14 2014-10-02 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
WO2016040896A1 (en) 2014-09-12 2016-03-17 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma

Also Published As

Publication number Publication date
CA2807149A1 (en) 2012-02-09
JP5998137B2 (ja) 2016-09-28
US20180296500A1 (en) 2018-10-18
US20150352060A1 (en) 2015-12-10
KR20130099928A (ko) 2013-09-06
KR20160010889A (ko) 2016-01-28
US20180116977A1 (en) 2018-05-03
US9132105B2 (en) 2015-09-15
IL224370B (en) 2018-04-30
MX345788B (es) 2017-02-15
US10245240B2 (en) 2019-04-02
US20170258744A1 (en) 2017-09-14
KR101594660B1 (ko) 2016-02-16
BR112013002655A2 (pt) 2016-05-31
AU2011285724A1 (en) 2013-03-21
KR20180010346A (ko) 2018-01-30
CN103124563A (zh) 2013-05-29
AU2011285724B2 (en) 2015-01-22
WO2012018948A3 (en) 2012-10-26
CN103124563B (zh) 2016-08-10
US9655868B2 (en) 2017-05-23
CA2807149C (en) 2017-05-02
US20130219528A1 (en) 2013-08-22
KR101926320B1 (ko) 2018-12-06
US9877932B2 (en) 2018-01-30
JP2013532733A (ja) 2013-08-19
EP2600855A2 (en) 2013-06-12
WO2012018948A2 (en) 2012-02-09
KR101823275B1 (ko) 2018-03-08

Similar Documents

Publication Publication Date Title
MX2013001272A (es) Nuevo tratamiento del carcinoma de prostata.
MX346147B (es) Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico.
NZ700759A (en) Combination therapy for treating cancer
MX2021002713A (es) Modulador del receptor de androgeno y usos de este.
IN2012MN02591A (es)
PH12014501560A1 (en) Carbamate compounds and of making and using same
MX349004B (es) Nuevos compuestos.
GB201118656D0 (en) New compounds
AU2011328009A8 (en) Compounds and methods for treating pain
WO2011017534A3 (en) Treatment of prostate cancer
MX366899B (es) Nuevos compuestos.
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MX356205B (es) Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
MY180613A (en) Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
IN2012DN02471A (es)
MX336761B (es) Compuestos para el tratamiento de cancer.
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
PH12016502244A1 (en) Hsp70 modulators and methods for making and using the same
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
WO2012158933A3 (en) Macrocycllc therapeutic agents and methods of treatment
SA515360377B1 (ar) نظائر خيمرية من سوماتوستاتين- دوبامين
HK1220356A1 (zh) 用於前列腺癌的新颖疗法
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2011007384A (es) Terapias de combinacion para trastornos neoplásticos.

Legal Events

Date Code Title Description
FG Grant or registration